Anticholinergic drugs and functional, cognitive impairment and behavioral disturbances in patients from a memory clinic with subjective cognitive decline or neurocognitive disorders

Abstract Background Drugs with anticholinergic properties may be associated with various adverse clinical effects. The relationship between the anticholinergic (AC) burden and functional, global cognitive performance and behavior disturbances was assessed among elderly patients. Methods A cross-sect...

Full description

Bibliographic Details
Main Authors: Virginie Dauphinot, Christelle Mouchoux, Sébastien Veillard, Floriane Delphin-Combe, Pierre Krolak-Salmon
Format: Article
Language:English
Published: BMC 2017-08-01
Series:Alzheimer’s Research & Therapy
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13195-017-0284-4
id doaj-11b61967d2be4e20a42c1789b252ae2d
record_format Article
spelling doaj-11b61967d2be4e20a42c1789b252ae2d2020-11-24T23:12:21ZengBMCAlzheimer’s Research & Therapy1758-91932017-08-019111110.1186/s13195-017-0284-4Anticholinergic drugs and functional, cognitive impairment and behavioral disturbances in patients from a memory clinic with subjective cognitive decline or neurocognitive disordersVirginie Dauphinot0Christelle Mouchoux1Sébastien Veillard2Floriane Delphin-Combe3Pierre Krolak-Salmon4Centre Mémoire de Ressources et de Recherche (CMRR) de Lyon, Hôpital des Charpennes, Hospices Civils de LyonCentre de Recherche Clinique (CRC) – VCF (Vieillissement–Cerveau–Fragilité), Hôpital des Charpennes, Hospices Civils de LyonCentre Mémoire de Ressources et de Recherche (CMRR) de Lyon, Hôpital des Charpennes, Hospices Civils de LyonCentre Mémoire de Ressources et de Recherche (CMRR) de Lyon, Hôpital des Charpennes, Hospices Civils de LyonCentre Mémoire de Ressources et de Recherche (CMRR) de Lyon, Hôpital des Charpennes, Hospices Civils de LyonAbstract Background Drugs with anticholinergic properties may be associated with various adverse clinical effects. The relationship between the anticholinergic (AC) burden and functional, global cognitive performance and behavior disturbances was assessed among elderly patients. Methods A cross-sectional study was conducted between January 2012 and June 2014 in a memory clinic among outpatients living at home and with subjective cognitive decline (SCD) or neurocognitive disorders (NCD). The AC burden was measured using the Anticholinergic Drug Scale (ADS), the Anticholinergic Risk Scale (ARS), the Anticholinergic Cognitive Burden (ACB), Chew’s score, Han’s score, and the number of drugs with AC activity. Functional, cognitive performance and behavior disturbances were assessed using the Instrumental Activities of Daily Living (IADL) scale (IADL), the Mini Mental State Examination (MMSE), and the Neuropsychiatric Inventory (NPI). Results Among 473 included patients, 46.3% were at major NCD. Patients took on average 5.3 ± 2.6 drugs. MMSE was lower when Han’s score (p = 0.04) and number of AC drugs were higher (p < 0.001). IADL was lower when AC burden was higher, whatever the AC measurement. NPI was higher when ACB, Han’s score, and number of AC drugs were higher. After adjustment, all AC scores remained associated with IADL, while Han’s score and number of drugs with AC remained associated with the MMSE. Conclusions In patients with SCD or NCD, AC burden is associated with lower functional score, whereas the cross-sectional association between AC burden and cognitive performance or behavioral disturbance varies according to AC scores. Particular attention should be paid when prescribing drugs with AC properties, especially among patients with memory complaints.http://link.springer.com/article/10.1186/s13195-017-0284-4Cognitive disorders and dementiaFunctional disordersAdverse effectsNeuropharmacology
collection DOAJ
language English
format Article
sources DOAJ
author Virginie Dauphinot
Christelle Mouchoux
Sébastien Veillard
Floriane Delphin-Combe
Pierre Krolak-Salmon
spellingShingle Virginie Dauphinot
Christelle Mouchoux
Sébastien Veillard
Floriane Delphin-Combe
Pierre Krolak-Salmon
Anticholinergic drugs and functional, cognitive impairment and behavioral disturbances in patients from a memory clinic with subjective cognitive decline or neurocognitive disorders
Alzheimer’s Research & Therapy
Cognitive disorders and dementia
Functional disorders
Adverse effects
Neuropharmacology
author_facet Virginie Dauphinot
Christelle Mouchoux
Sébastien Veillard
Floriane Delphin-Combe
Pierre Krolak-Salmon
author_sort Virginie Dauphinot
title Anticholinergic drugs and functional, cognitive impairment and behavioral disturbances in patients from a memory clinic with subjective cognitive decline or neurocognitive disorders
title_short Anticholinergic drugs and functional, cognitive impairment and behavioral disturbances in patients from a memory clinic with subjective cognitive decline or neurocognitive disorders
title_full Anticholinergic drugs and functional, cognitive impairment and behavioral disturbances in patients from a memory clinic with subjective cognitive decline or neurocognitive disorders
title_fullStr Anticholinergic drugs and functional, cognitive impairment and behavioral disturbances in patients from a memory clinic with subjective cognitive decline or neurocognitive disorders
title_full_unstemmed Anticholinergic drugs and functional, cognitive impairment and behavioral disturbances in patients from a memory clinic with subjective cognitive decline or neurocognitive disorders
title_sort anticholinergic drugs and functional, cognitive impairment and behavioral disturbances in patients from a memory clinic with subjective cognitive decline or neurocognitive disorders
publisher BMC
series Alzheimer’s Research & Therapy
issn 1758-9193
publishDate 2017-08-01
description Abstract Background Drugs with anticholinergic properties may be associated with various adverse clinical effects. The relationship between the anticholinergic (AC) burden and functional, global cognitive performance and behavior disturbances was assessed among elderly patients. Methods A cross-sectional study was conducted between January 2012 and June 2014 in a memory clinic among outpatients living at home and with subjective cognitive decline (SCD) or neurocognitive disorders (NCD). The AC burden was measured using the Anticholinergic Drug Scale (ADS), the Anticholinergic Risk Scale (ARS), the Anticholinergic Cognitive Burden (ACB), Chew’s score, Han’s score, and the number of drugs with AC activity. Functional, cognitive performance and behavior disturbances were assessed using the Instrumental Activities of Daily Living (IADL) scale (IADL), the Mini Mental State Examination (MMSE), and the Neuropsychiatric Inventory (NPI). Results Among 473 included patients, 46.3% were at major NCD. Patients took on average 5.3 ± 2.6 drugs. MMSE was lower when Han’s score (p = 0.04) and number of AC drugs were higher (p < 0.001). IADL was lower when AC burden was higher, whatever the AC measurement. NPI was higher when ACB, Han’s score, and number of AC drugs were higher. After adjustment, all AC scores remained associated with IADL, while Han’s score and number of drugs with AC remained associated with the MMSE. Conclusions In patients with SCD or NCD, AC burden is associated with lower functional score, whereas the cross-sectional association between AC burden and cognitive performance or behavioral disturbance varies according to AC scores. Particular attention should be paid when prescribing drugs with AC properties, especially among patients with memory complaints.
topic Cognitive disorders and dementia
Functional disorders
Adverse effects
Neuropharmacology
url http://link.springer.com/article/10.1186/s13195-017-0284-4
work_keys_str_mv AT virginiedauphinot anticholinergicdrugsandfunctionalcognitiveimpairmentandbehavioraldisturbancesinpatientsfromamemoryclinicwithsubjectivecognitivedeclineorneurocognitivedisorders
AT christellemouchoux anticholinergicdrugsandfunctionalcognitiveimpairmentandbehavioraldisturbancesinpatientsfromamemoryclinicwithsubjectivecognitivedeclineorneurocognitivedisorders
AT sebastienveillard anticholinergicdrugsandfunctionalcognitiveimpairmentandbehavioraldisturbancesinpatientsfromamemoryclinicwithsubjectivecognitivedeclineorneurocognitivedisorders
AT florianedelphincombe anticholinergicdrugsandfunctionalcognitiveimpairmentandbehavioraldisturbancesinpatientsfromamemoryclinicwithsubjectivecognitivedeclineorneurocognitivedisorders
AT pierrekrolaksalmon anticholinergicdrugsandfunctionalcognitiveimpairmentandbehavioraldisturbancesinpatientsfromamemoryclinicwithsubjectivecognitivedeclineorneurocognitivedisorders
_version_ 1725601210231160832